Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $495,056.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $16.00, for a total transaction of $495,056.00. Following the completion of the sale, the chief operating officer owned 575,235 shares of the company’s stock, valued at approximately $9,203,760. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total transaction of $484,845.47.

Adaptive Biotechnologies Price Performance

Adaptive Biotechnologies stock traded down $0.51 during mid-day trading on Thursday, hitting $15.93. The company’s stock had a trading volume of 1,850,817 shares, compared to its average volume of 1,676,883. The business has a 50 day moving average price of $16.83 and a 200-day moving average price of $15.79. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -39.82 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company’s quarterly revenue was up 51.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.23) earnings per share. On average, equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. BTIG Research lifted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Finally, Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results and revenue beat — Adaptive reported stronger-than-expected Q4 results (EPS beat and revenue +51% YoY), which supports longer-term growth expectations and was a catalyst for bullish analyst notes earlier this quarter. MarketBeat ADPT page
• Positive Sentiment: Analyst backdrop mostly constructive — Multiple firms have buy/overweight ratings and recent price-target increases (consensus “Moderate Buy”), which provides support vs. headline volatility. Analyst coverage summary
• Neutral Sentiment: Short-interest data shows an anomalous 0-share reading and a 0.0 days-to-cover metric — this appears to be a data/reporting artifact rather than a meaningful change in bearish positioning. (No actionable signal until corrected data is posted.)
• Neutral Sentiment: Small institutional activity — several modest new or increased stakes were reported in recent filings; institutional ownership remains high (~99%). These moves are small relative to market cap and unlikely to drive intraday price action. Institutional holdings
• Negative Sentiment: Large CEO selling — CEO Chad Robins has executed multiple large sales, including a 289,024‑share sale on Mar. 2 at ~$15.82 (~$4.57M) and other recent disposals totaling hundreds of thousands of shares; these sizable reductions (one filing showed a ~12.7% position cut) are a near-term negative signal for investor sentiment. CEO sale SEC filing
• Negative Sentiment: Other insider sales — COO Julie Rubinstein sold ~30.9k shares (filings show sales at ~$15.67–$16.00 for ~$485k–$495k), and director/insider Harlan Robins sold multiple blocks (10k and ~14.2k shares). Multiple insider sales in a short window amplify market concern about near-term insider conviction. COO sale SEC filing Harlan sale SEC filing

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC boosted its holdings in shares of Adaptive Biotechnologies by 3.1% in the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after acquiring an additional 700 shares in the last quarter. Bouvel Investment Partners LLC lifted its position in shares of Adaptive Biotechnologies by 2.2% during the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after acquiring an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Adaptive Biotechnologies by 3.1% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock worth $355,000 after acquiring an additional 910 shares in the last quarter. California State Teachers Retirement System raised its holdings in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after buying an additional 933 shares during the period. Finally, Captrust Financial Advisors grew its position in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after purchasing an additional 1,119 shares in the last quarter. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.